File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice

TitleVirulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice
Authors
Issue Date2005
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
Citation
Journal Of Infectious Diseases, 2005, v. 192 n. 4, p. 665-672 How to Cite?
AbstractBackground. Control of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic. Methods. BALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN 1203/04) virus. Five- and 8-day regimens were evaluated. Results. Oseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P < .01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P < .05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P < .01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect. Conclusions. Oseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule. © 2005 by the Infectious Diseases Society of America. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/179783
ISSN
2015 Impact Factor: 6.344
2015 SCImago Journal Rankings: 4.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYen, HLen_US
dc.contributor.authorMonto, ASen_US
dc.contributor.authorWebster, RGen_US
dc.contributor.authorGovorkova, EAen_US
dc.date.accessioned2012-12-19T10:04:34Z-
dc.date.available2012-12-19T10:04:34Z-
dc.date.issued2005en_US
dc.identifier.citationJournal Of Infectious Diseases, 2005, v. 192 n. 4, p. 665-672en_US
dc.identifier.issn0022-1899en_US
dc.identifier.urihttp://hdl.handle.net/10722/179783-
dc.description.abstractBackground. Control of highly pathogenic avian H5N1 influenza viruses is a major public-health concern. Antiviral drugs could be the only option early in the pandemic. Methods. BALB/c mice were given oseltamivir (0.1, 1, or 10 mg/kg/day) twice daily by oral gavage; the first dose was given 4 h before inoculation with H5N1 A/Vietnam/1203/04 (VN 1203/04) virus. Five- and 8-day regimens were evaluated. Results. Oseltamivir produced a dose-dependent antiviral effect against VN1203/04 in vivo (P < .01). The 5-day regimen at 10 mg/kg/day protected 50% of mice; deaths in this treatment group were delayed and indicated the replication of residual virus after the completion of treatment. Eight-day regimens improved oseltamivir efficacy, and dosages of 1 and 10 mg/kg/day significantly reduced virus titers in organs and provided 60% and 80% survival rates, respectively (P < .05). Overall, the efficacy of the 5- and 8-day regimens differed significantly (death hazard ratio, 2.658; P < .01). The new H5N1 antigenic variant VN1203/04 was more pathogenic in mice than was A/HK/156/97 virus, and a prolonged and higher-dose oseltamivir regimen may be required for the most beneficial antiviral effect. Conclusions. Oseltamivir prophylaxis is efficacious against lethal challenge with VN1203/04 virus in mice. Viral virulence may affect the antiviral treatment schedule. © 2005 by the Infectious Diseases Society of America. All rights reserved.en_US
dc.languageengen_US
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.orgen_US
dc.relation.ispartofJournal of Infectious Diseasesen_US
dc.subject.meshAcetamides - Administration & Dosageen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntiviral Agents - Administration & Dosageen_US
dc.subject.meshBrain - Virologyen_US
dc.subject.meshCell Lineen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshFemaleen_US
dc.subject.meshGuanidinesen_US
dc.subject.meshInfluenza A Virus - Drug Effects - Pathogenicityen_US
dc.subject.meshInhibitory Concentration 50en_US
dc.subject.meshLung - Virologyen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshOrthomyxoviridae Infections - Drug Therapyen_US
dc.subject.meshOseltamiviren_US
dc.subject.meshPyransen_US
dc.subject.meshSialic Acids - Pharmacologyen_US
dc.subject.meshVirulenceen_US
dc.subject.meshVirus Replication - Drug Effectsen_US
dc.subject.meshZanamiviren_US
dc.titleVirulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in miceen_US
dc.typeArticleen_US
dc.identifier.emailYen, HL: hyen@hku.hken_US
dc.identifier.authorityYen, HL=rp00304en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1086/432008en_US
dc.identifier.pmid16028136-
dc.identifier.scopuseid_2-s2.0-23244456655en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23244456655&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume192en_US
dc.identifier.issue4en_US
dc.identifier.spage665en_US
dc.identifier.epage672en_US
dc.identifier.isiWOS:000231019500015-
dc.publisher.placeUnited Statesen_US
dc.identifier.f10001027117-
dc.identifier.scopusauthoridYen, HL=7102476668en_US
dc.identifier.scopusauthoridMonto, AS=7004552306en_US
dc.identifier.scopusauthoridWebster, RG=36048363100en_US
dc.identifier.scopusauthoridGovorkova, EA=7003837718en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats